Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab']
#ash22 abstract 441 - et al. off-treatment progression is uncommon in highly refractory patients with lbcl who are in cr at the end of fixed-course glofitamab treatment. just published in 
Hematologist at Saint Antoine Hospital, Paris, France @Sorbonne_Univ_ @APHP. @JACIE_EBMT National Representative. #BMTsm #LYMsm #CARTcell #CardioOnc #QoL